Syntrax LipoKinetix Liver AERs Necessitate Product Removal – FDA
This article was originally published in The Tan Sheet
Executive Summary
LipoKinetix should be withdrawn from the market due to reports linking the weight-loss supplement to "at least six" cases of serious liver injury, FDA states in a 1Nov. 19 letter to Chaufee, Mo.-based Syntrax Innovations